Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens

This study is ongoing, but not recruiting participants.

Sponsored by:	Allergopharma Joachim Ganzer KG
Information provided by:	Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier:	NCT00666341

Purpose

Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)

Condition	Intervention	Phase
Type I-Allergy	Other: placebo Biological: AL0701rP	Phase II

Drug Information available for: Aluminum hydroxide Algeldrate Aluminum

Study Type:	Interventional
Official Title:	A Double-Blind Placebo-Controlled Dose-Response Study for Evaluation of Safety and Efficacy of Immunotherapy With a Cocktail of Recombinant Major Allergens of Timothy Grass Pollen (Phleum Pratense) Adsorbed to Aluminium Hydroxide in Patients With IgE-Mediated Allergic Rhinitis/Rhinoconjunctivitis With or Without Bronchial Asthma

Further study details as provided by Allergopharma Joachim Ganzer KG:

Primary Outcome Measures:

Eligibility

Criteria

Inclusion Criteria:

main symptoms of allergic rhinitis/rhinoconjunctivitis with or without controlled asthma against grass pollen allergens
positive SPT
positive EAST
positive specific provocation test

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00666341

Locations

Sponsors and Collaborators

Allergopharma Joachim Ganzer KG

Investigators

Study Chair:

Karl Hörmann, MD

Universitätsklinikum Mannheim GMBH

More Information

Leader in specific allergy research and therapy This link exits the ClinicalTrials.gov site

Study ID Numbers:	AL0701rP
Study First Received:	April 21, 2008
Last Updated:	October 14, 2008
ClinicalTrials.gov Identifier:	NCT00666341
Health Authority:	Germany: Paul-Ehrlich-Institut

Study placed in the following topic categories:

Hypersensitivity
Asthma
Rhinitis
Aluminum Hydroxide

ClinicalTrials.gov processed this record on January 16, 2009